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Abstract
Nontransformed breast epithelial cells that are adjacent to tumor cells are constantly exposed to tumor necrosis
factor–α (TNFα) and interleukin-1β (IL-1β), two inflammatory cytokines identified as having pro-tumoral causative
roles. We show that continuous stimulation of nontransformed breast epithelial cells by TNFα + IL-1β for 2 to
3 weeks induced their spreading and epithelial-to-mesenchymal transition (EMT). The mechanistic bases for this
slow induction of EMT by TNFα + IL-1β are: 1) it took 2 to 3 weeks for the cytokines to induce the expression of
the EMT activators Zeb1 and Snail; 2) although Twist has amplified the EMT-inducing activities of Zeb1 + Snail, its
expression was reduced by TNFα + IL-1β; however, the lack of Twist was compensated by prolonged stimulation
with TNFα + IL-1β that has potentiated the EMT-inducing activities of Zeb1 + Snail. Stimulation by TNFα + IL-1β
has induced the following dissemination-related properties in the nontransformed cells: 1) up-regulation of func-
tional matrix metalloproteinases; 2) induction of migratory and invasive capabilities; 3) disruption of the normal
phenotype of organized three-dimensional acini structures typically formed only by nontransformed breast cells
and spreading of nontransformed cells out of such acini. Our findings suggest that TNFα + IL-1β induce dis-
semination of nontransformed breast epithelial cells and their reseeding at the primary tumor site; if, then, such
detached cells are exposed to transforming events, they may form secondary malignant focus and lead to disease
recurrence. Thus, our study reveals novel pathways through which the inflammatory microenvironment may
contribute to relapsed disease in breast cancer.
Neoplasia (2013) 15, 1330–1346
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Introduction
Breast cancer evolves out of multifactorial and dynamic processes,
which are greatly influenced by the tumor microenvironment. Domi-
nated by inflammatory traits, the tumor milieu in breast cancer is
enriched with inflammatory cytokines that very often fail to induce
immune protective mechanisms but rather skew the balance toward
tumor-promoting events. Thus, multifaceted activities exerted by
inflammatory cytokines on stroma cells, leukocytes, and the tumor
cells themselves lead to increased angiogenesis, tumor growth and
progression, and eventually aggravate disease course [1–4].
In this context, major tumor-promoting roles were recently attrib-
uted to the cytokines tumor necrosis factor–α (TNFα) and interleukin-
1β (IL-1β). These two cytokines are minimally expressed by normal
breast epithelial cells; however, both TNFα and IL-1β are expressed by
breast tumor cells in the majority of breast cancer patients, with pro-
nounced expression of both cytokines in >80% of patients who have
experienced relapse [5–16]. In murine breast model systems, TNFα
induces many cancer-promoting functions, and inhibiting TNFα ex-
pression leads to reduced breast malignancy [17–26]. Thus, in contrast
to previous studies suggesting that local administration of TNFα directly
into tumors may kill cancer cells, many researchers now consider TNFα
a factor whose chronic expression at the tumor microenvironment leads
to a more aggressive tumor phenotype, including in breast cancer [26–
29]. Similarly, IL-1β, shown to upregulate a variety of processes that
contribute to higher angiogenesis, tumor growth, and progression in
breast cancer, is considered a strong and causative pro-malignancy factor
whose expression is associated with advanced disease [5–9,16,30–37].
Within the large diversity of the tumor-promoting functions exerted
by TNFα and IL-1β, their ability to induce cell remodeling in breast
cancer cells was recently discovered. Several publications, including
from our group, indicate that TNFα and IL-1β increase tumor cell
spreading, epithelial-to-mesenchymal transition (EMT), and invasive-
ness of breast tumor cells [16,38–43]. EMT is a process in which the
tumor cells lose epithelial markers that are required for cell-to-cell ad-
hesion, such as E-cadherin, and acquire mesenchymal properties that
promote tumor cell motility and invasiveness, like vimentin [44–48].
In breast cancer, EMT was strongly linked to tumor aggressiveness and
metastasis [49–52]; thus by inducing EMT, TNFα and IL-1βmanifest
yet another level by which the inflammatory microenvironment can
promote disease course.
TNFα and IL-1β, both expressed simultaneously in the majority
of breast cancer patients with relapsed disease [16], may affect not
only cancer cells and cells of the tumor microenvironment but also
breast epithelial cells that are present in proximity to the tumor cells
and are yet nontransformed. Recent findings have provided sporadic
evidence to the ability of TNFα to affect cell morphology and pos-
sibly EMT in nontransformed breast epithelial cells [53–55]; how-
ever, these studies were performed mainly when TNFα was combined
with the strong EMT inducer transforming growth factor–β, they did
not address the important and most clinically relevant aspect of com-
bined TNFα + IL-1β activities, and they did not provide profound
systematic analysis of the mechanisms involved in cell remodeling
induced by the cytokines in breast epithelial nontransformed cells.
In the present study, we have addressed these issues and provided
in-depth understanding of the effects of TNFα, IL-1β, and both
cytokines together on cell plasticity, EMT, and dissemination of
nontransformed breast epithelial cells. Briefly, in response to TNFα +
IL-1β stimulation, nontransformed breast epithelial cells acquired
high spreading capabilities and underwent EMT. Mechanistic analysis
indicated that induction of EMT required prolonged stimulation of
the cells by TNFα + IL-1β and this was because of complex regulatory
processes of the EMT activators Zeb1, Snail, and Twist. When analyz-
ing the functional implications of cell remodeling and EMT induced by
TNFα + IL-1β stimulation, we found that the two cytokines together
have induced high release of matrix metalloproteinases (MMPs) by the
cells, migration, invasion, distortion of three-dimensional (3D) acini
structures that are typically formed only by nontransformed breast
epithelial cells [56,57], and spreading of the nontransformed cells out
of such ordered acini structures.
Overall, the findings of this study suggest that nontransformed breast
epithelial cells located in TNFα + IL-1β–enriched tumors respond to
the two cytokines by increased EMT, migration, and invasion. As a
result of these processes, nontransformed breast epithelial cells may
detach and migrate out of normally organized breast structures that
may have still remained in proximity to the tumor, disseminate, and
reseed at the primary tumor site. Such cells may be then exposed to
transforming events prevalent at the inflammatory microenvironment
of breast tumors, such as nitric oxide (NO) that induces mutagenesis
[58–60]. Such a process may consecutively lead to formation of a
new tumor focus adjacent to the primary focus, where the tumor was
initiated. These events may stand on the basis of cases of breast cancer
recurrence, which have been highly correlated with elevated expression
of TNFα + IL-1β [16] and thus have major clinical implications.
Materials and Methods
Cells
The nontransformed human breast epithelial MCF-10A cells
[61,62] (kindly provided by Prof. Berger, Chaim Sheba Medical
Center, Tel-Hashomer, Israel) were maintained in Dulbecco’s modified
Eagle’s medium–F12 medium, supplemented with 5% horse serum,
10 μg/ml insulin, 2 ng/ml epidermal growth factor, 100 U/ml penicil-
lin, 100 μg/ml streptomycin (all purchased from Biological Industries,
Beit Haemek, Israel), 100 ng/ml cholera toxin (Sigma-Aldrich,
St Louis, MO), and 0.5 μg/ml hydrocortisone (Sigma). The non-
transformed human mammary epithelial HB2 cells (a clonal deriva-
tive of the nontumorigenic mammary epithelial cell line, MTSV1-7
[63,64]; kindly provided by Prof. Tsarfaty, Tel Aviv University, Tel
Aviv, Israel) were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum, 10 μg/ml insulin, and
0.5 μg/ml hydrocortisone (Biological Industries). In some of the experi-
ments (see details below), the cells were transferred to serum-free
medium before the actual tests were performed: MCF-10A cells were
transferred to LPM medium (Biological Industries), and HB2 cells
were transferred to their corresponding serum-free medium.
Stimulation by Cytokines
In all parts of this study, the cells were stimulated by recombinant
human (rh) TNFα at 50 ng/ml (Cat. No. 300-01A; PeproTech, Rocky
Hill, NJ), rhIL-1β at 500 pg/ml (Cat. No. 200-01B; PeproTech), or
both cytokines together (termed TNFα + IL-1β; concentrations as
above). These cytokine concentrations were selected on the basis of
dose-response analyses that were performed in our laboratory, using
induction of inflammatory chemokines by breast tumor cells as read-
outs of TNFα- and IL-1β–induced effects (data not shown). On the
basis of these analyses, we chose TNFα and IL-1β doses that gave
prominent impact on chemokine release but were not at the highest
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end of the concentration range. So far, published reports on TNFα and
IL-1β levels in breast tumors in patients presented the data as “cytokine
concentration per tissue weight” [5,6] (at the low range of dose spec-
trum), thus we cannot conclude whether the concentrations used in our
study are within the amounts existing in tumors (as we used them in
“cytokine concentration per volume” values). Nevertheless, it is impor-
tant to mention that the concentrations of TNFα and IL-1β that we
used are relatively low, are not inducing death or necrosis of the cells
(high TNFα doses of ∼1-4 mg, which are used for loco-regional treat-
ments, cause necrosis [65]), and are within the conventional scale used
by other investigators. Control nonstimulated cells were exposed to the
solubilizer of the cytokines (0.1% BSA).
In experiments analyzing chemokine induction by ELISA, the cells
were stimulated by the cytokines for 24 hours only, in serum-free
medium, allowing processes of chemokine production and accumula-
tion in conditioned media (CM) to take place. In cell remodeling and
EMT-related studies, the cells were stimulated with the cytokines for
3 to 4 weeks in growth medium containing serum. Fresh cytokines
were replenished every 3 to 4 days (after removal of previous cytokine-
containing medium). Twenty-four to 48 hours before the cell remodel-
ing and EMT-related assays (e.g., flow cytometry, MMP production,
invasion, and migration), the growth medium was replaced by serum-
free medium containing the cytokines (unless otherwise indicated).
Control cells were grown under similar conditions, albeit in the absence
of cytokines (they were replaced by their solubilizer). In specific cases
that are mentioned in the text and figure legends, a short stimulation
of 3 days was also included in the cell remodeling analyses.
Enzyme-Linked Immunosorbent Assays
To determine the release of CXCL8 and CCL2 by TNFα- and
IL-1β–stimulated cells, the nontransformed breast epithelial cells were
stimulated by the cytokines for 24 hours, as described above. Then,
ELISA analyses were performed, and CXCL8 and CCL2 levels
in CM were determined using standard curves with rhCXCL8 or
rhCCL2 (Cat. No. 200-08 and No. 300-04, respectively; PeproTech),
at the linear range of absorbance. The following antibodies were used
(all from PeproTech): for CXCL8—coating polyclonal antibodies
(Cat. No. 500-P28), detecting biotinylated rabbit polyclonal anti-
bodies (Cat. No. 500-P28Bt); for CCL2—coating monoclonal anti-
bodies (Cat. No. 500-M71), detecting biotinylated rabbit polyclonal
antibodies (Cat. No. 500-P34Bt). After the addition of streptavidin-
HRP (Jackson ImmunoResearch Laboratories, West Grove, PA), the
substrate TMB/E solution (Chemicon, Temecula, CA) was added.
The reaction was stopped by the addition of 0.18 M H2SO4 and
was measured at 450 nm.
Determination of Cell Morphology
Cells were stimulated by the cytokines for up to 3 weeks, as de-
scribed above (except that the growth medium was not exchanged to
serum-free medium). During this time course, cell morphology was
determined by microscopy at 1-week intervals (see figures; Eclipse
Ti; Nikon, Melville, NY), and the cells were photographed (NIS-
Elements version 4.0). Magnification of ×10 to ×20 was used, as
indicated in the figure legends.
Formation of 3D Acini Structures
MCF-10A and HB2 cells were infected to express mCherry (with
pQC-mCherry retroviral vector), and formation of 3D acini structures
was performed as previously described [56,57]. Briefly, eight-well
chamber slides (Nunc, Rochester, NY) were coated with 40 to
50 μl of ice-cold liquid Matrigel (Cat. No. 356234; BD Biosciences,
Bedford, MA) that has solidified for 15 minutes at 37°C. Later, 5 ×
103 MCF-10A cells or 2.4 × 103 HB2 cells were seeded in each well
of the chamber, in 400 μl of 2% Matrigel-containing medium. Be-
cause acini have not been previously described in HB2 cells, we have
verified that these cells indeed formed the hollow structures that are
typical of acini [56,57]. To this end, fluorescence z-stack images were
captured with a confocal laser scanning microscope, using two-photon
laser for optical imaging (LSM 510; Carl Zeiss, Jena, Germany).
Three-dimensional surface renderings were generated from the z-stack
confocal images, using ImageJ software.
In this study, 3D acini structures were formed under two cytokine-
stimulatory conditions in which the cells were exposed to the cytokines
for 3 weeks (without exchange to serum-free medium) under the
following stimulatory setups: 1) Formation of acini by cells that have
been already stimulated by TNFα + IL-1β: Cells were stimulated by
the cytokines (concentrations as above) for 3 weeks, in 2D standard
cultures. Control nonstimulated cells (exposed to the solubilizer of
the cytokines) and the cytokine-stimulated cells were seeded on top
of Matrigel-coated wells to allow for acini structures to be formed.
Pictures of the cells were taken 7 days after seeding, by laser scanning
confocal microscope (CLSM510, Zeiss). 2) Stimulation of pre-formed
acini by TNFα + IL-1β: Nonstimulated cells were seeded on top of
Matrigel-coated wells and were allowed to grow for 6 days, until 3D
structures were starting to form. Then, the cells were either stimulated
by TNFα + IL-1β (concentrations as above) or not (control cells,
stimulated by the solubilizer of the cytokines) for additional 2 weeks.
At that point, pictures of the structures were taken by laser scanning
confocal microscope (CLSM510, Zeiss).
Flow Cytometry
Cells were stimulated by the cytokines for up to 3 to 4 weeks
in serum-containing growth medium. At specific time points (see
figures), the cells were analyzed by flow cytometry. Before this analy-
sis, the cells were incubated overnight in serum-free medium in the
presence of the cytokines (or their solubilizer), and then the expres-
sion of E-cadherin and vimentin was determined as previously de-
scribed [16]. Briefly, E-cadherin surface expression was determined
by mouse IgG1 antibodies against human E-cadherin (Cat. No.
SC-21791; Santa Cruz Biotechnology, Santa Cruz, CA). Determina-
tion of vimentin expression was performed in methanol-permeabilized
cells using mouse IgG1 antibodies against human vimentin (Cat.
No. SC-6260; Santa Cruz Biotechnology). Baseline staining was
obtained by nonrelevant isotype control IgG1 antibodies (Cat.
No. 400101; BioLegend, San Diego, CA). Then, the cells were stained
by fluorescein isothiocyanate–conjugated goat anti-mouse IgG1 (Cat.
No. 115-095-003; Jackson ImmunoResearch Laboratories). Staining
was determined by flow cytometry with a Becton Dickinson FACSort
(Mountain View, CA) and the win MDI software.
Vimentin expression score was calculated as (mean fluorescence) ×
(percentage of positive cells). The score obtained for control non-
stimulated cells was given the value of 1, and the value for TNFα +
IL-1β–stimulated cells was calculated relative to the control cells.
shRNAs for Zeb1 and Snail and Overexpression of Zeb1,
Snail, and Twist
Down-regulation of Zeb1 and Snail expressionwas performed by infection
with Zeb1 short hairpin RNA (shRNA; Cat. No. RHS4529-NM_030751;
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Open Biosystems, Huntsville, AL; kindly provided by Prof. Rotter,
Weizmann Institute of Science, Rehovot, Israel) or with Snail shRNA
(Cat. No. SHCLNG-NM_005985; Sigma-Aldrich; kindly provided
by Prof. Reich, The Hebrew University of Jerusalem, Jerusalem,
Israel). For both targets, several different shRNAs were assayed
and the most effective ones were chosen for use throughout the
study. Following infection, selection was performed with 6 μg/ml
puromycin (A.G. Scientific, San Diego, CA). Then, the cell popu-
lation was used as a whole to prevent bias toward specific cell clones.
Control cells were infected with control shRNA vectors carrying simi-
lar antibiotic resistance. Down-regulation of Zeb1 and Snail was
verified by quantitative real-time polymerase chain reaction (qPCR)
analyses, using the primers and conditions indicated below in the qPCR
Analyses section.
To induce overexpression of Zeb1, Zeb1 cDNA (Cat. No.
MHS4426-98361372; Open Biosystems) was obtained and was then
amplified by using the following sequences of primer pairs: HA tag
and the Age1 restriction site were added to the forward primer
5′-CACACAACCGGTATGTACCCTTACGACGTTCCTGAT-
TACGCTAGCCTCATGGCGGATGGCCCCAGGTGTAA-3′,
and the BamH1 restriction site was added to the reverse primer
5′-GTGTGTGGATCCCGATTAGGCTTCATTTGTCTTTTCT-
TCA-3′. The reaction conditions were given as follows: 94°C for
3 minutes, and then two cycles of 94°C for 30 seconds, 60°C for
30 seconds, and 72°C for 4 minutes. Annealing was performed at
68°C for 30 seconds, followed by 30 amplification cycles of 72°C
for 10 minutes. The amplified Zeb1 fragment was inserted to the
pQCXIN vector (neomycin resistant).
To induce overexpression of Snail and of Twist1 (to be hereby
termed Twist), total RNA was isolated from human HB2 cell line.
Full-length cDNA was amplified by reverse transcriptase–PCR. The
sequences of the primer pairs used for Snail fragment amplification
were given as follows: Myc tag and the Age1 restriction site were added
to the forward primer 5′-TCTCTCACCGGTATGGAACAAAAAC-
TCATCTCAGAAGAGGATCTGATGCCGCGCTCTTTCCTCG-
TCAGGAA-3′, and the BamH1 restriction site was added to the
reverse primer 5′-AAATCTGGATCCTCAGCGGGGACATCCT-
GAGCAG-3′. The sequences of the primers used for Twist fragment
amplification were given as follows: HA tag and the Age1 restriction
site were added to the forward primer 5′-AGAGAGACCGGTAT-
GGGATCCTACCCTTACGACGTTCCTGATTAC-3′, and the
BamH1 restriction site was added to the reverse primer 5′-AGGA-
GAGGATCCCTAGTGGGACGCGGACATGGA-3′. The reaction
conditions were given as follows: 94°C for 3 minutes, and then
two cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C
for 4 minutes. Annealing was performed at 68°C for 30 seconds, fol-
lowed by 40 amplification cycles of 72°C for 10minutes. The amplified
Snail fragment was inserted to the pQCXIH vector (hygromycin resis-
tant), and the Twist fragment was inserted into the pQCXIP vector
(puromycin resistant).
Following the above, the cloned sequences of Zeb1, Snail, and
Twist were verified by GenBank sequences. Then, the cells were
infected with the relevant vectors or with control vectors, and fol-
lowing selection (500 μg/ml neomycin, 200 μg/ml hygromycin, or
6 μg/ml puromycin, as appropriate), in each infection type, the cell
population was used as a whole to prevent bias toward specific cell
clones. The overexpression of Zeb1, Snail, and Twist was verified
by qPCR, using the primers and conditions described below in the
qPCR Analyses section.
qPCR Analyses
qPCR analyses of Zeb1, Snail, and Twist were performed in
two conditions: 1) following stimulation by the cytokines; in this
case, the cells were stimulated for 3 days or 3 weeks in serum-
containing growth medium, which was replaced by serum-free medium
at the last 48 hours of stimulation; 2) following down-regulation or
overexpression of Zeb1, Snail, or Twist (in different combinations, as
appropriate; see Results section).
Total RNA was isolated from the cells using the EZ-RNA kit
(Biological Industries), and first-strand cDNA was produced using
the M-MLV reverse transcriptase (Ambion, Austin, TX). Quantifica-
tion of cDNA targets by qPCR was performed using Rotor Gene 6000
(Corbett Life Science, Sydney, Australia) and the Rotor Gene 6000
series software. Transcripts were detected using SYBRGreen I (Thermo
Fisher Scientific, Waltham, MA) according to the manufacturer’s
instructions. The primers were given as follows: Zeb1: forward
5′-TGCAGCTGACTGTGAAGGTGT-3′, reverse 5′-CTTGCCC-
TTCCTTTCTGTCATC-3′; Snail: forward 5′-CTAATCCAGAGT-
TTACCTTCCAGCA-3′, reverse 5′-AGTCCCAGATGAGCATT-
GGC-3′; Twist: forward 5′-GGCCGGAGACCTAGATGTCA-3′,
reverse 5′-CCACGCCCTGTTTCTTTGAATT-3′; rS9 (normalizing
gene): forward 5′-TTACATCCTGGGCCTGAAGAT-3′, reverse
5′-GGGATGTTCACCACCTGCTT-3′. PCR amplification was
performed over 40 cycles (95°C for 15 seconds, 59°C for 20 seconds,
72°C for 15 seconds). Dissociation curves for each primer set indi-
cated a single product, and “no template” controls were negative after
40 cycles. Quantification was performed by standard curves on the
linear range of quantification.
Gelatin Substrate Zymography
The cells were stimulated for 3 weeks by the cytokines and then
were plated onto 24-well plates in serum-containing growth medium.
After an overnight incubation in serum-free medium in the presence of
the cytokines, CM were collected for determination of MMP activities.
In parallel, cells in each treatment were counted for further per-cell-
basis quantitation of MMP secretion (see below). CM were centrifuged
and then were separated on sodium dodecyl sulfate–polyacrylamide
gel electrophoresis containing 0.1% gelatin substrate. After electro-
phoresis, gels were washed in 50 mM Tris HCl, pH 7.5, containing
2.5% Triton X-100. The gels were then washed three times in
50 mM Tris HCl buffer, pH 7.4, followed by incubation in buffer
consisting of 50 mM Tris HCl, pH 7.4, 0.02% NaN3, and 10 mM
CaCl2 for 48 hours at 37°C. After three washes in double-distilled
H2O, the gels were stained with 0.1% Coomassie blue and destained
in 20% methanol and 10% acetic acid. Then, clear bands of protein
degradation, indicating the presence of enzymatically active MMPs,
were visualized.
Invasion Assays
The invasion potential of the cells was determined in transwell
migration chambers with 8-μm pore size, polycarbonate membrane
plates (Cat. No. 3422; Costar, Cambridge, MA), as previously de-
scribed [16]. Briefly, the membranes located in the upper wells were
pre-coated with Matrigel (as above) for 1 hour at 37°C, then block-
ing was performed for 1 hour with 0.1% heat-inactivated BSA. Cells
that have been either stimulated by the cytokines or nonstimulated
(exposed to the solubilizer of the cytokines) for 3 weeks in serum-
containing medium were suspended in serum-free medium and were
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added to the upper wells of the chamber on top of the membrane,
in the presence or absence of cytokine stimulation, as appropriate.
Following 2 hours of incubation in 37°C, the upper wells were put
on the lower wells of the chamber, containing medium supplemented
with 10% serum. Both the upper and lower wells of the chamber
included cytokines, thus preventing formation of a cytokine gradient
in the course of the assay. Following incubation for 8 hours at 37°C,
the nonmigrated cells on the upper surface of the membrane were
completely removed by wiping with a cotton swab. Next, the filters
were fixed and were stained with Hemacolor for microscopy (Cat.
No. 1.11661; Merck, Darmstadt, Germany). The invaded cells were
photographed (Olympus DP70 Digital Camera; Olympus America
Inc, Center Valley, PA) and then counted in high power fields by light
microscopy (Eclipse TE2000-S; Nikon).
Wound Healing Assays
The nontransformed cells, stimulated for 3 weeks by the cytokines
or nonstimulated (exposed to the solubilizer of the cytokines) in
serum-containing growth medium, were seeded in six-well tissue
culture plates and have reached confluence in the presence of the
cytokines. A wound was incised in the central area of the confluent
culture using a plastic tip, followed by careful two washing steps of
the detached cells and addition of fresh serum-free medium. Closure
of the denuded area was monitored using an inverted microscope
(Eclipse TS-100; Nikon) fitted with a digital camera (DX-FI1; Nikon).
The wounded area was followed and documented at the time of the
scratching and following 20 hours. Of note, in separate analyses, cell
counts indicated that TNFα and IL-1β did not induce growth of the
nontransformed breast epithelial cells.
Statistical Analyses
Statistical analyses were done using Student’s t tests. Values of
P < .05 were considered statistically significant. In each type of ex-
perimental analysis, the results are of a representative experiment of
at least three independent repeats, showing similar results (in rare
cases, when more appropriate, the results were presented as average
of several experiments). In each representative experiment, data are
presented as means ± SD of technical repeats within the experiment
(when appropriate). When required, adjustment for multiplicity of
comparisons was done using the Benjamini-Hochberg procedure.
Using this procedure, all the significant results that are presented in
the manuscript remained statistically significant after correcting for
their multiplicity.
Results
Continuous Stimulation by TNFα + IL-1β Leads to
Cell Remodeling and EMT in Nontransformed Breast
Epithelial Cells
Primary tumors in breast cancer are enriched with both TNFα
and IL-1β [5–16], which may affect adjacent nontransformed cells
in a cooperative manner. Before determining the impact of the
two cytokines on cell remodeling and EMT properties in the non-
transformed cells, we asked to what extent these cells respond to
TNFα and IL-1β, and if the two cytokines can act in concert, as
may be expected by their joint expression in the majority of breast
cancer patients [16].
As proxies for responsiveness to TNFα and IL-1β, we used in-
duction of the inflammatory chemokines CXCL8 and CCL2. In
the immune context, TNFα and IL-1β are powerful inducers of
inflammatory chemokines, as is the case in tumor cells, including
breast cancer cells [26,66–72]. In many malignancies, including
breast cancer, CXCL8 and CCL2 are well identified as potent
tumor-promoting factors [73–78], and thus their induction provides
a relevant readout for responsiveness of the nontransformed breast
epithelial cells to TNFα and IL-1β. The results presented in Figure 1
indicate that nontransformed MCF-10A and HB2 breast epithelial
cells indeed responded to TNFα and IL-1β stimuli by significant ele-
vations in CXCL8 and CCL2. Moreover, cooperativity was observed
between TNFα and IL-1β in inducing CXCL8 in both cell types and
also in CCL2 induction in HB2 cells (Figure 1). Of note, MCF-10A
cells responded to TNFα and IL-1β stimulation more potently than
HB2, and this may be due to intrinsic differences in the expression
levels of receptors for the cytokines or of the downstream signaling
pathways that evolved.
To follow on the above findings, we determined the joint impact
of TNFα and IL-1β together (namely, TNFα + IL-1β) and of each
cytokine alone on induction of spreading and invasion-related properties
in the nontransformed cells. First, we performed kinetics analyses
in which we followed the morphology of stimulated and nonstimulated
cells for 3 weeks. We found that IL-1β, but much more strongly TNFα
and TNFα + IL-1β, induced cell remodeling and morphology changes
in both MCF-10A cells (Figure 2A) and HB2 cells (Figure 2B). How-
ever, in contrast to tumor cells in which it took 1 to 3 days for such a
process to develop (e.g., in our studies of MCF-7 cells [16] and in other
investigations [38,42,43]), in the nontransformed cells 2 to 3 weeks of
stimulation were necessary for induction of cell remodeling, visualized
by cell spreading and formation of cellular protrusions (Figure 2).
In view of the above results and of the ability of TNFα and IL-1β
to induce EMT in breast tumor cells, we performed a detailed analy-
sis of the ability of the two cytokines to induce EMT in the two non-
transformed breast epithelial cells, MCF-10A and HB2, analyzing
each cytokine alone and both of them together. To determine the
impact of the cytokines on EMT, we began by using the following
two most typical EMT markers: 1) reduction in cell surface expres-
sion of E-cadherin, indicative of loss of cell-to-cell contacts and 2)
up-regulation of vimentin expression, manifesting acquisition of a
mesenchymal phenotype by the cells [44–48]. After 3 weeks of stim-
ulation, both MCF-10A cells and HB2 cells manifested reduced
expression levels of E-cadherin, particularly following stimulation
by TNFα and TNFα + IL-1β (Figure 3, A and B). In parallel,
vimentin expression was elevated in the two cell lines following
TNFα and TNFα + IL-1β stimulations, whereas IL-1β alone was a
weak/noninducer of vimentin expression (Figure 3, C and D). Of
interest, following TNFα + IL-1β exposure a certain part of the cell
population of MCF-10A cells has gained increased expression of
vimentin per cell (indicated by increased mean fluorescence values),
whereas in HB2 cells a new subpopulation has emerged, which was
characterized with particularly high expression levels of vimentin
(indicated in Figure 3D by an arrow). In view of its separable
and very definitive phenotype, this high vimentin-expressing sub-
population of HB2 cells had a clear advantage in analyzing EMT
processes in a quantitative manner and thus was used along the study
as a proxy for measuring EMT events. Using this high vimentin-
expressing subpopulation of HB2 cells, we found that stimulation
of the nontransformed cells by TNFα + IL-1β for 3 days indeed
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was not sufficient for induction of EMT in these cells, but rather 2 to
3 weeks were required (data not shown), as was also indicated by the
morphology observations presented in Figure 2B.
Thus, the above results indicate that TNFα was a more prominent
inducer of cell remodeling and EMT-related characteristics in non-
transformed cells than IL-1β. Furthermore, highly potent activities
were also induced by the combination of TNFα + IL-1β, which
recapitulates the high co-expression of the two cytokines together in
the majority of breast cancer patients, particularly in >80% patients
with recurrent disease [16]. In view of the high clinical relevance of
the combined TNFα + IL-1β stimulation, and due to the advantage
expressed by the joint stimulation in induction of CXCL8 and CCL2
compared to stimulation by each cytokine alone (Figure 1), further
analyses focused on the combined stimulation of the cells by TNFα +
IL-1β together.
Specifically, we asked whether nontransformed epithelial breast cells
that were stimulated by the cytokines will be able to form multicellular
organized structures that are typical of normal breast cells. To investi-
gate this issue, we employed the commonly used model of 3D acini
structures, formed in nonadherent conditions on Matrigel by non-
transformed breast epithelial cells but not by malignant cells
[56,57]. Formation of 3D acini structures has been well described
for the MCF-10A cells [56,57], and we have followed published pro-
tocols to establish such acini of MCF-10A cells in our current study.
Using acini structures as platform to decipher perturbations of normal
textures, we investigated the ability of nontransformed cells that have
been stimulated for 3 weeks by TNFα + IL-1β and have undergone
EMT to form acini. To this end, MCF-10A cells were stimulated for
3 weeks by the cytokines and then were allowed to form acini on
Matrigel, in comparison to nonstimulated cells. We found that the
control nonstimulated cells have established multicellular organized
structures, whereas the cytokine-stimulated cells did not form such
structures in the majority of cases (Figure 4A). Moreover, the cytokine-
stimulated cells—which have been already exposed to TNFα + IL-1β
for 3 weeks—have gained very potent spreading abilities and degraded
the matrix when they were plated on Matrigel to form acini. Therefore,
the acini formation process in this type of experiment could not be
followed for more than 6 days because the process of acini establish-
ment has began (instead of 2 to 3 weeks that are usually required),
and this is why the control nonstimulated cells did not form yet the
hollow structures typical of acini [56,57], although as indicated, they
already made organized multicellular structures (Figure 4A).
In parallel to MCF-10A cells, we have established acini with HB2
cells. Because this is the first demonstration of acini formation by
HB2 cells, we show in Figure W1 that these cells indeed formed
hollow structures as they should (Figure W1). After the method
was set, we have tested the ability of cytokine-stimulated HB2 cells
to form acini. The findings with HB2 cells (Figure 4B) were similar
to those obtained with MCF-10A cells (Figure 4A): Instead of adher-
ing to each other and forming cell-to-cell contacts required for acini
Figure 1. Nontransformed breast epithelial cells respond to TNFα and IL-1β by increased release of the pro-malignancy chemokines
CXCL8 and CCL2. MCF-10A cells (A, B) and HB2 cells (C, D) were stimulated by TNFα (50 ng/ml), IL-1β (500 pg/ml), or both cytokines
together (TNFα + IL-1β; concentrations as above) for 24 hours, in serum-free medium. Cytokine concentrations for stimulation were
selected on the basis of previous titration analyses (see Materials and Methods section for details; data not shown). Control, cells not
stimulated by the cytokines (exposed to the solubilizer of the cytokines). The expression levels of CXCL8 (A, C) and CCL2 (B, D) were
determined in cell supernatants by ELISA, in the linear range of absorbance. ***P < .001 for cytokine-stimulated cells compared to
nonstimulated cells. In all panels, a representative experiment of n = 3 is presented.
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formation, the cells have detached from each other and have formed
cellular protrusions, characteristic of cells undergoing EMT (as was
shown in Figure 2B). Note that as with MCF-10A cells, the control
nonstimulated cells did not have enough time (only 6 days) to form
hollow acini structures, but they already established multicellular
textures, as expected (Figure 4B).
Taken together, the above results indicate that TNFα + IL-1β
stimulation has induced cell plasticity, spreading and EMT in the
non-transformed breast epithelial cells. This has been visualized by
extensive formation of cell protrusions, down-regulation of the epi-
thelial marker E-cadherin, elevation in expression of the mesenchymal
marker vimentin, and inability to form acini.
Figure 2. Prolonged stimulation by TNFα and IL-1β induces morphologic changes, spreading, and formation of cellular protrusions
in nontransformed breast epithelial cells. MCF-10A cells (A) and HB2 cells (B) were stimulated by TNFα, IL-1β, or TNFα + IL-1β
(concentrations as in Figure 1). Control, cells not stimulated by the cytokines (exposed to the solubilizer of the cytokines). Cell images
were taken immediately after cell culturing (time 0) and then after 1, 2, and 3 weeks of stimulation, at ×10 to ×20 magnification
(×10 magnification was used only for HB2 cells, in which case photographs were adjusted to ×20 magnification digitally). Arrows point
to some of the cells in which cellular protrusions and spreading have been observed. In all panels, the images are representatives of
many pictures taken in n = 3 experiments.
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Figure 3. Continuous stimulation by TNFα and IL-1β leads to reduced surface expression of E-cadherin and increased expression of vimentin
in nontransformed breast epithelial cells. MCF-10A cells (A, C) and HB2 cells (B, D) were stimulated by TNFα, IL-1β, or TNFα + IL-1β
(concentrations as in Figure 1) for 3 weeks. Control, cells not stimulated by the cytokines (exposed to the solubilizer of the cytokines).
Surface expression of E-cadherin was determined in intact cells (A, B), while intracellular expression of vimentin was determined in per-
meabilized cells (C, D), using flow cytometry. Isotype, nonrelevant isotype control. The arrow points out the new subpopulation of cells with
high expression of vimentin that has appeared following TNFα+ IL-1β stimulation in HB2 cells. In all panels, a representative experiment of
at least n = 3 is presented.
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The Need for Continuous and Prolonged Stimulation
by TNFα + IL-1β for Induction of EMT in Breast
Nontransformed Cells Is due to Imbalance in the
Activation Profiles of EMT Inducers
As indicated above, the fact that full-blown EMT was induced in
nontransformed breast epithelial cells only after 2 to 3 weeks of
stimulation by TNFα + IL-1β contrasted the rapid kinetics of the same
process induced by the cytokines (each alone) in malignant breast cells
that took 1 to 3 days to develop [16,38,42,43]. Furthermore, using the
subpopulation of high vimentin-expressing HB2 cells as proxy for
EMT, we found that EMT induction by the cytokines required per-
sistent presence of TNFα + IL-1β (Figure W2). This was indicated by
the fact that when the stimulation by TNFα + IL-1β was removed, the
EMT phenotype has been gradually extinguished (Figure W2).
To provide mechanistic insights into the regulatory events dictating
the slow EMT process in the nontransformed cells, we focused on
Zeb1, Snail, and Twist, known as key inducers of EMT in breast tumor
cells [46–52,79–89]. Time-dependent analyses of HB2 cells, using the
high vimentin-expressing subpopulation as indicator of EMT, have
shown that following 3 days of stimulation by TNFα + IL-1β—which
is a time point that is insufficient for induction of EMT in these
cells (Figure 2B)—none of these three EMT activators was induced
(Figure 5A). Here, it is important to indicate that in breast tumor cells,
Figure 4. Nontransformed breast epithelial cells stimulated by
TNFα + IL-1β are incapable of forming organized acini structures.
MCF-10A cells (A) and HB2 cells (B) were stimulated by TNFα +
IL-1β (concentrations as in Figure 1) for 3 weeks. Control, cells not
stimulated by the cytokines (exposed to the solubilizer of the cyto-
kines). Then, the cells were plated onto nonadherent conditions
on Matrigel to allow for acini formation. After 7 days, pictures of
the structures were taken by confocal microscopy. In all panels,
the images are representatives of many pictures taken in n = 3
experiments. See text (Results section) for explanation on the acini
structures formed by the control nonstimulated cells.
Figure 5. Continuous stimulation by TNFα + IL-1β induces up-
regulation in Zeb1 and Snail expression and downregulates Twist
expression in nontransformed breast epithelial cells. HB2 cells
were stimulated by TNFα, IL-1β, or TNFα + IL-1β (concentrations
as in Figure 1) for 3 days (A) or for 2 to 3 weeks (B). Control, cells
not stimulated by the cytokines (exposed to the solubilizer of the
cytokines). At each time point, the expression of Zeb1, Snail, and
Twist was determined by qPCR. **P < .01, ***P < .001; NS, not
significant for cytokine-stimulated cells compared to nonstimulated
cells. Nonstimulated cells were given the value of 1. In all panels,
a representative experiment of n = 3 is presented.
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in which EMT was induced already after 1 to 3 days [16,38,42,43],
we found that Zeb1 and Snail were elevated in much more rapid
kinetics and were increased within 3 days of stimuli (data not shown).
In contrast to the 3-day stimulation process that did not promote any
of the EMT inducers, a totally different pattern was revealed after 2 to
3 weeks of stimulation by TNFα + IL-1β, which are the conditions
leading to EMT in these cells: Zeb1 and Snail were eventually up-
regulated, and in parallel, down-regulation in the expression of Twist
was detected (Figure 5B).
These results suggested that the delayed activation of Zeb1 and
Snail and down-regulation of Twist stand on the basis of the slow
activation process of EMT that was induced by TNFα + IL-1β in
the nontransformed cells. To see if this was the case, first we analyzed
the regulation of the EMT process in these cells by Zeb1 and Snail. As
a result of Zeb1 or Snail down-regulation by shRNAs (Figure W3),
the TNFα + IL-1β–induced EMT process was blocked even when
4 weeks of cytokine stimulation were introduced (Figure 6, A–D
for Zeb1 and Figure 6, E–H for Snail). This was indicated by the
inability of TNFα + IL-1β to induce up-regulation of the high
vimentin-expressing subpopulation in cells experiencing Zeb1 or Snail
down-regulation (due to expression of shRNAs). Furthermore, we
found that overexpression of Zeb1 + Snail in the cells (Figure W4A)
has potently induced the EMT process, as indicated by elevation in
vimentin expression (Figure 7A). These findings indicated that Zeb1
and Snail were EMT inducers in the nontransformed breast epithelial
cells, they were essential for TNFα + IL-1β–induced EMT in these
cells, and thus their delayed induction following cytokine stimulation
prevented earlier activation of the EMT process (Figure 5B).
In parallel to Zeb1 and Snail, we analyzed the roles played by
Twist in EMT induction in the nontransformed cells in response to
TNFα + IL-1β. Because prolonged stimulation of the cells by TNFα
+ IL-1β has led to down-regulation of Twist expression (Figure 5B), we
decided to learn more on the roles of Twist in EMT induction in the
nontransformed cells by inducing its overexpression in these cells and
determining its impact on EMT, using vimentin expression as readout.
The results of Figure 7B indicate that the overexpression of Twist in
the cells (Figure W4B) has not induced EMT. However, the roles of
Twist in EMT induction were revealed when it was combined with
Zeb1 and Snail. The addition of Twist to Zeb1 + Snail overexpression
has amplified the EMT process that now exceeded the levels obtained
by Zeb1 + Snail by themselves (Figure 7A).
The reduction in Twist expression by the prolonged stimulation
with TNFα + IL-1β has led us to ask if the two cytokines may com-
pensate for the lack of Twist expression. Indeed, we found that TNFα +
IL-1β stimulation has amplified the ability of Zeb1 + Snail to induce
EMT (Figure 7, C–E), as was previously noticed for Twist when it was
combined with Zeb1 + Snail (Figure 7A). To potentiate the activities of
Zeb1 + Snail, 2 to 3 weeks of stimulation by TNFα + IL-1β were
required, indicating that while the cytokines have downregulated Twist
expression, they have recapitulated its missing activities in a process
requiring prolonged stimulation.
Taken together, the findings obtained in this part of the study
indicate that to induce EMT, TNFα + IL-1β had to stimulate the cells
for prolonged durations of 2 to 3 weeks and that the delayed EMT
process was due to the following two reasons: 1) It took 2 to 3 weeks
for the cytokines to induce the expression of Zeb1 and Snail, which
were required for TNFα + IL-1β–induced EMT processes in these
cells (Figures 5, 6, and 7A); 2) 2 to 3 weeks of stimulation were
required for the cytokines to take over the missing activities of Twist
and to further amplify the EMT-inducing activities of Zeb1 + Snail
(Figure 7, A and C–E).
Stimulation of Nontransformed Breast Epithelial Cells by
TNFα + IL-1β Leads to Dissemination-Related Functions
and to Cell Spreading Out of Organized Acini Structures
To follow on the cell remodeling and EMT processes induced by
TNFα + IL-1β in the nontransformed cells (Figures 2–4), we have
determined the functional implications of cytokine stimulation.
Here, we focused on activities that may lead to dissemination of
the nontransformed cells at the primary tumor site, turning these
cells later to potential targets for transformation and formation of a
new tumor focus.
The results of Figure 8A indicate that TNFα + IL-1β stimulation
of the nontransformed cells has given rise to pronounced induction
of active MMP2 and MMP9, in levels similar to those induced by
TNFα alone, and much more pronounced than the levels induced by
IL-1β alone. Furthermore, nontransformed cells stimulated by the
cytokines have gained potent invasive properties, as indicated by
invasion assays performed through Matrigel-coated membranes in
response to serum-containing medium in transwells. The invasion
assays emphasized once again the functional benefit of the combined
stimulation by the two cytokines together compared to each alone
(Figure 8, B and C ; note that none of the stimulations affected
significantly the basal migration phenotype of the cells, determined
in response to serum-free medium; Figure W5). IL-1β was a weak
inducer of invasion (Figure 8, B and C ), agreeing well with its lower
ability to induce spreading and EMT in these cells (Figures 2–4).
Although TNFα has induced invasion more efficiently than IL-1β,
the greatest impact on invasion was revealed upon combined stimu-
lation by TNFα + IL-1β, being in line with the most effective ability
of these two cytokines to act together and lead to preferential induction
of CXCL8 and CCL2 (Figure 1). This combined stimulation has also
promoted considerably the migratory properties of the nontransformed
cells, as indicated by wound closure assays of motility (Figure 8D; note
that cytokine stimulation did not induce the growth of the cells; data
not shown).
The above findings provide evidence to the eminent power of the
combined stimulation by TNFα + IL-1β in inducing dissemination-
related properties in the nontransformed breast epithelial cells. The
question that followed was whether cytokine stimulation would dis-
rupt those structures that are normally established in the breast by
nontransformed cells. To answer this question, we used again the
acini structures, as they represent the organized cellular texture estab-
lished by normal breast epithelial cells, and their perturbation is often
used to investigate mechanisms involved in tumor initiation and pro-
gression [56,57]. Specifically, we asked how the cytokines will affect
the organization of acini that have been already formed. Thus, acini
were allowed to start forming for 1 week without cytokine stimula-
tion, and then the structures were grown for additional 2 weeks with
or without TNFα + IL-1β stimulation. The findings of Figure 9
indicate that the control nonstimulated cells have established organized
multicellular hollow acini structures as expected, while the stimula-
tion by the cytokines has led to total disruption of the well-ordered
acini structures: In the majority of the acini that were stimulated by
TNFα + IL-1β, the nontransformed cells have spread out of the acini,
demonstrating an unorganized distribution of cells and collapse of the
previously organized acini structure (Figure 9).
Neoplasia Vol. 15, No. 12, 2013 Nontransformed Cells: Inflammation, Plasticity Leibovich-Rivkin et al. 1339
Figure 6. Zeb1 and Snail are essential for EMT induction in nontransformed breast epithelial cells stimulated by TNFα + IL-1β. HB2 cells
were infected to express shRNA to Zeb1, shRNA to Snail, or control shRNA vector (down-regulation of Zeb1 and Snail expression was
verified by qPCR, as shown in Figure W3). The cells were either stimulated by TNFα + IL-1β (concentrations as in Figure 1) for 1 or
4 weeks or nonstimulated by the cytokines (exposed to the solubilizer of the cytokines) for the same time course. Following down-
regulation of these factors and cytokine stimulation, the expression of vimentin was determined by flow cytometry in permeabilized
cells, as proxy for cells undergoing EMT. Isotype, nonrelevant isotype control. (A–D) The impact of Zeb1 down-regulation on EMT.
(A, C) Cells grown with or without cytokine stimulation for 1 week. (B, D) Cells grown with or without cytokine stimulation for 4 weeks.
(A, B) Cells infected with control vector. (C, D) Cells infected with shRNA for Zeb1. (E–H) The impact of Snail down-regulation on EMT.
(E, G) Cells grown with or without cytokine stimulation for 1 week. (F, H) Cells grown with or without cytokine stimulation for 4 weeks.
(E, F) Cells infected with control vector. (G, H) Cells infected with shRNA for Snail. The arrows point out the new subpopulation of cells
with high expression of vimentin that has appeared following cytokine stimulation in control HB2 cells and has disappeared upon
down-regulation of Zeb1 and Snail. In all panels, a representative experiment of at least n = 3 is presented.
1340 Nontransformed Cells: Inflammation, Plasticity Leibovich-Rivkin et al. Neoplasia Vol. 15, No. 12, 2013
Overall, the results presented in this part of the study indicate that
TNFα + IL-1β, which have been shown to be highly expressed in
the breast tumor microenvironment [5–16], induced in nontrans-
formed breast epithelial cell processes of motility and invasion, lead-
ing to cell migration out of normally organized breast textures of
acini. The outcome of such events may be dissemination of the yet
nontransformed epithelial cells at the tumor site, and if these cells are
then exposed to transforming events, they may be the “cornerstone” of
new tumor focus that will be formed in close proximity to the primary
tumor site.
Discussion
The tumor microenvironment of breast tumors is enriched with
inflammatory mediators, including the cytokines TNFα and IL-1β that
are highly released by the cancer cells [5–16]. The two cytokines are
expressed together in tumors of most patients with recurrent disease
[16] and have been shown to have causative pro-tumoral activities.
TNFα and IL-1β promote breast malignancy by many different func-
tions that are exerted on leukocytes and stroma cells and on the
tumor cells themselves [16–26,30–37]. Between others, the two
cytokines were found to induce EMT in breast tumor cells and
causatively contributed to increased disease course [16,38–43].
The novel findings obtained in this study demonstrate the strong
impact of joint TNFα + IL-1β stimulation on cell remodeling and
plasticity of nontransformed breast epithelial cells; it provides mecha-
nistic understanding of the events mediating these activities of the
two cytokines and illustrates the functional implications and the clini-
cal relevance of these findings. Our results show that in response to the
two cytokines together, these nontransformed cells have spread con-
siderably, underwent EMT, and exhibited the important functional
readouts of MMP production, increased motility, and invasiveness.
Of major importance are the findings showing that the stimulation
of the nontransformed cells by TNFα + IL-1β has led to spread-
ing of cells out of the organized structures that are typical of normal
breast cells (acini). Thus, it is possible that nontransformed cells
that have remained in the breast tissue in proximity to tumor cells
Figure 7. The EMT-inducing activities of Zeb1 and Snail on nontransformed breast epithelial cells are potentiated by Twist or alternatively
by prolonged stimulation with TNFα+ IL-1β. HB2 cells were infected to overexpress Zeb1+ Snail or Twist + Zeb1+ Snail (A) or Twist alone
(B) (the increased expression of these EMT inducers following infectionwas verified by qPCR, as shown in FigureW4). Control, cells infected
with control vector. Following expression of these factors, the expression of vimentin was determined by flow cytometry in permeabilized
cells, as proxy for cells undergoing EMT. Isotype, nonrelevant isotype control. In all panels, a representative experiment of n = 3 is pre-
sented. (C–E) HB2 cells were infected to overexpress Zeb1 + Snail (termed “Zeb + Snail”; the expression of these EMT inducers following
infection was verified by qPCR as shown in Figure W4). The cells were either not stimulated by the cytokines (exposed to the solubilizer
of the cytokines) or stimulated for 1 week (C), 2 weeks (D), or 3 weeks (E) by TNFα + IL-1β (concentrations as in Figure 1; termed “Zeb +
Snail, TNFα + IL-1β”). At each time point, the expression of vimentin was determined by flow cytometry in permeabilized cells, as proxy
for cells undergoing EMT. Isotype, nonrelevant isotype control. In all panels, a representative experiment of n = 3 is presented.
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would disseminate at the primary tumor site and may be the target of
transformation thereafter.
Here, it is interesting to indicate that in contrast to breast tumor cells
in which the cytokines induced EMT rapidly following 1 to 3 stim-
ulation days [16,38,42,43], in the nontransformed cells the pro-
cess was characterized by much slower kinetics, and only after
2 to 3 weeks of stimulation by TNFα + IL-1β cell remodeling
and EMT were induced (Figures 2 and 5). In our investigation,
Figure 8. TNFα+ IL-1β induce high MMP levels and increased invasive and migratory phenotype in nontransformed breast epithelial cells.
HB2 cells were stimulated by TNFα, IL-1β, or TNFα + IL-1β (concentrations as in Figure 1) for 3 weeks. Control, cells not stimulated by the
cytokines (exposed to the solubilizer of the cytokines). (A) Release of functional MMPs. CM were collected, and the presence of active
MMPs was determined by zymography. A representative experiment of n = 3 is presented. (B, C) Invasion through Matrigel, determined
after 8 hours in response to serum-containing medium, in transwells. Of note, the constitutive level of basal migration (no serum included)
was not affected by cytokine stimulation (Figure W5). In cytokine-stimulated groups, TNFα and/or IL-1β were present throughout the time
of assay in the upper wells to enable constant stimulation and also in the bottom wells of the chamber to prevent cytokine gradients.
(B) Representative images of cells that have invaded, in control and cytokine-stimulated groups. In all panels, the images are representa-
tives of many pictures taken in n = 3 experiments. (C) Quantitative analysis of the number of cells that have invaded in each of the groups.
**P < .01, ***P < .001 for cytokine-stimulated cells compared to nonstimulated cells. In all panels, a representative experiment of n = 3
is presented. (D) Migration in wound closure assays. Following plating, the cells reached full confluence and a scratch was performed.
Images of the cells were taken at the time of scratching (wound: 0 hour) and after 20 hours (wound: 20 hours). TNFα+ IL-1β were present
throughout the time of assay, and in parallel analyses were not found to induce cell growth (data not shown). In all panels, the images
are representatives of many pictures taken in n = 3 experiments.
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we provided mechanistic explanation to the delayed EMT kinetics
and to nonconventional regulatory events that took place in the non-
transformed breast epithelial cells following stimulation by TNFα +
IL-1β. We demonstrated that the delayed induction of EMT was
the direct result of imbalance in the regulation of Zeb1, Snail, and
Twist, indicated by 1) delayed activation of Zeb1 and Snail induced
by TNFα + IL-1β stimulation and 2) induction of cooperativity
between TNFα + IL-1β and Zeb1 + Snail that took time to develop.
These results add another layer of complexity to the regulation of
EMT processes that have been already revealed in breast tumor
cells. Indeed, in breast cancer cells, these three regulators were found
to have cardinal involvement in inducing EMT, invasiveness, and
metastasis, and the majority of studies of breast cancer patients pro-
vide evidence to correlations between high expression levels of Zeb1,
Snail, and/or Twist with EMT and with aggressive tumor phenotype
[46–52,79–89]. However, in parallel, complex interactions between
these three regulators were revealed in several studies, suggesting
that the equilibrium between them may dictate the extent of EMT,
invasiveness, and disease course [46–48,90,91].
The TNFα + IL-1β–induced processes of EMT and plasticity in
nontransformed breast epithelial cells may have high relevance to
what may be happening in breast tumors. In patients’ tumors, non-
transformed epithelial cells that are still present in the tissue are con-
stantly exposed to TNFα + IL-1β [5–16], expressed together at high
levels in >80% of the patients with relapsed disease [16]. One of the
characteristics of such patients is local recurrence of tumor growth in
the breast. With the improvement of diagnostic measures, nowadays
it is known that recurrent ipsilateral breast tumors may be due to one
of two scenarios: 1) true local recurrence—regrowth of malignant cells
that were not killed by radiotherapy or not removed by surgery; 2) new
primary tumors—cases that have developed de novo at the primary
tumor site. In new primary tumors, the cancer cells may exhibit differ-
ent markers and genetic setup compared to the original primary tumor
[92–95]. Such a phenomenon can take place if nontransformed cells
that were present at the initial tumor focus have migrated away from
the primary site and have been exposed later to transforming events,
for example, the mutagenizing factor nitric oxide that is prevalent at
the inflammatory microenvironment of breast tumors [58–60].
On the basis of our results, we suggest that such a possibility may
evolve when TNFα and IL-1β are expressed at high levels at the tumor
site and induce EMT, MMP production, and invasion out of ordered
breast structures in nontransformed breast epithelial cells. As a result,
the nontransformed cells may acquire high migratory and invasive
properties, may disseminate in the tissue, and seed themselves in proxi-
mal sites. If then, following the TNFα + IL-1β–induced dissemina-
tion of the nontransformed cells and their reseeding in the vicinity
to the primary tumor site, they would be exposed to mutagenizing
agents, they may undergo malignant transformation. Under such
circumstances, a new tumor focus will develop in proximity to the
primary focus, carrying genetic properties and markers that are dif-
ferent from the first tumor (as has been described in breast cancer;
[92–95]). The continuous need for TNFα + IL-1β stimulation to
induce invasive properties and consequently dissemination of the non-
transformed cells may be one of the reasons of long duration until
recurrence occurs in some of the patients.
In this way, a devastating interaction would exist between high
TNFα and IL-1β levels, plasticity and EMT-related processes taking
place in breast epithelial cells that have not been transformed as yet,
disease recurrence and relapse. Such mechanisms may act in parallel
to processes taking place in breast tumor cells, in which EMT events
were suggested to promote tumor recurrence [96,97]. Most impor-
tantly, our study suggests that it is the inflammatory microenvironment
that can promote plasticity, EMT, spreading, and invasion of non-
transformed cells. Eventually, by acting in such a manner, the inflam-
matory microenvironment would dictate not only the elevated growth
of primary tumors and their metastatic dissemination to remote
organs but also whether the patients will develop secondary tumors
and will succumb to disease recurrence.
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Figure W1. Acini structure formed by HB2 cells. Nonstimulated HB2
cells were plated in nonadherent conditions on Matrigel to allow for
acini formation. After 2 weeks, acini structures were pictured by
confocal microscopy, using two-photon laser for optical imaging,
showing the hollow structure of the acini.
Figure W2. The EMT process, induced in nontransformed breast
epithelial cells by TNFα + IL-1β, is reversible. HB2 cells were
stimulated by TNFα + IL-1β (TNFα, 50 ng/ml; IL-1β, 500 pg/ml)
for 4 weeks. Then, the cytokines were removed, and the cells were
grown for additional 4 weeks without the cytokines. Vimentin
expression was determined as proxy for EMT processes, once a
week along this time course by flow cytometry in permeabilized
cells. The results are expressed by arbitrary units of vimentin
expression, calculated as described in Materials and Methods sec-
tion. At each time point, vimentin expression in control nonstimu-
lated cells (exposed to the solubilizer of the cytokines) was given
the value of 1 and is presented as dashed line. The results are of
X ± SD of n = 3.
Figure W3. Validation of Zeb1 and Snail down-regulation following expression of shRNA to Zeb1 and Snail. HB2 cells were infected with
shRNA to Zeb1, shRNA to Snail, or control shRNA vector. A week after selection, the expression of (A) Zeb1 or (B) Snail was validated
by qPCR. The results were normalized to the values obtained by the rS9 gene. *P < .05, **P < .01 for cells infected with shRNAs to
Zeb1/Snail compared to cells infected by control vector. In both panels, a representative experiment of n = 3 is presented.
Figure W4. Validation of overexpression of EMT regulators. HB2 cells were infected to overexpress (A) Zeb1 + Snail, (B) Twist, or
(C) Twist + Zeb1 + Snail. Control, cells infected with control vector. A week following selection, the overexpression of Zeb1, Snail,
or Twist, as appropriate, was validated by qPCR. The results were normalized to the values obtained by the rS9 gene. ***P < .001 for
cells infected to overexpress the EMT inducers compared to cells infected with control vector. In all panels, a representative experiment
of n = 3 is presented.
Figure W5. Theconstitutive level of basal invasionof nontransformed
breast epithelial cells is not modified by cytokine stimulation. HB2
cells were stimulated by TNFα, IL-1β, or TNFα + IL-1β (concentra-
tions as in Figure 1) for 3 weeks. These cells were tested in the
serum-induced invasion assays shown in Figure 8, B and C , and
in parallel, their spontaneous basal invasion toward serum-free
medium was determined following 8 hours of cytokine stimulation.
In cytokine-stimulated groups, TNFα and/or IL-1β were present
throughout the time of assay in the upper wells to enable constant
stimulation and also in the bottom wells of the chambers to prevent
cytokine gradients. The results are of X ± SD of n = 3.
